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Abstract
Understanding human physiological responses to high-fat energy excess (HFEE) 
may help combat the development of metabolic disease. We aimed to investigate 
the impact of manipulating the n-3PUFA content of HFEE diets on whole-body and 
skeletal muscle markers of insulin sensitivity. Twenty healthy males were overfed 
(150% energy, 60% fat, 25% carbohydrate, 15% protein) for 6 d. One group (n = 10) 
received 10% of fat intake as n-3PUFA rich fish oil (HF-FO), and the other group 
consumed a mix of fats (HF-C). Oral glucose tolerance tests with stable isotope 
tracer infusions were conducted before, and following, HFEE, with muscle biop-
sies obtained in basal and insulin-stimulated states for measurement of membrane 
phospholipids, ceramides, mitochondrial enzyme activities, and PKB and AMPKα2 
activity. Insulin sensitivity and glucose disposal did not change following HFEE, 
irrespective of group. Skeletal muscle ceramide content increased following HFEE 
(8.5 ± 1.2 to 12.1 ± 1.7 nmol/mg, p =  .03), irrespective of group. No change in 
mitochondrial enzyme activity was observed following HFEE, but citrate synthase 
activity was inversely associated with the increase in the ceramide content (r=−0.52, 
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1 |  INTRODUCTION
Dietary energy and fat overconsumption leading to body 
mass gain is associated with the development of obesity and 
insulin resistance (Chan et al.,  1994; Colditz et al.,  1995). 
High-fat, high-energy diets have become increasingly com-
mon, particularly in Western countries, and are thought to 
contribute to insulin resistance and type 2 diabetes (T2D) 
(Van Dam et al., 2002). Investigation of the early physiolog-
ical responses of humans to dietary fat and energy excess is 
important to improve our understanding of the chronic (mal)
adaptations that lead to obesity, insulin resistance, and T2D, 
and to inform the development of targeted preventative strat-
egies to address these early responses.
Short-term consumption of a high-fat energy excess 
(HFEE) diet is a model that has been widely used to investi-
gate mechanisms leading to diet-induced insulin resistance. 
Experimental studies that increased dietary intake of saturated 
fats (SFA) demonstrate reductions in whole-body insulin sen-
sitivity (Bachmann et al., 2001; Hulston et al., 2015; Parry 
et al., 2017; Parry et al., 2019). However, studies using equal 
proportions of the three main classes of fats (SFA, monoun-
saturated (MUFA), and polyunsaturated (PUFA)) have failed 
to demonstrate an influence of overfeeding on whole-body 
measures of insulin sensitivity (Adochio et al., 2009; Brøns 
et al., 2009; Cornier et al., 2006). While a diet rich in SFA 
is typically related to the development of obesity and T2D 
(Van Dam et al., 2002), consuming long chain n-3 polyunsat-
urated fatty acids (n-3PUFAs) appears to have clinical benefit 
in reducing the development of insulin resistance (Fedor & 
Kelley, 2009). Hence, there is clear rationale that the fat com-
position of HFEE diets could modulate the metabolic conse-
quences of overfeeding.
At the cellular level, an accumulation of lipid moieties 
including ceramides, diacylglycerols, and long chain fatty 
acyl-CoAs in insulin-receptive skeletal muscle tissue charac-
terizes insulin resistance (Holland et al., 2007; Zierath, 2007). 
The accumulation of ceramides in skeletal muscle of obese, 
insulin-resistant individuals is coupled with a downregula-
tion of insulin signaling, including decreased phosphoryla-
tion of PKBSer473 and PKBThr308 (Adams et  al.,  2004), and 
impaired mitochondrial function (Holloway et al., 2009), pos-
sibly driven by reduced AMPK activity (O'Neill et al., 2012; 
Steinberg et  al.,  2006). The pharmacological activation 
of AMPK has been shown to increase fatty acid oxidation 
(Dzamko & Steinberg, 2009; O’Neill et al., 2012), whereas 
reduced AMPK activity is associated with decreased fatty 
acid oxidation within skeletal muscle (O’Neill et al., 2012; 
Steinberg et al., 2006). Interestingly, mitochondrial oxidative 
capacity is increased in response to HFEE in animal models 
(Hancock et al., 2008; Jain et al., 2014; Turner et al., 2007), 
but this mitochondrial upregulation has not been demon-
strated in humans (Samocha-Bonet et  al.,  2012; Toledo 
et al., 2018). Thus, developing a better understanding of the 
relationships between HFEE, skeletal muscle oxidative ca-
pacity, and lipid-induced changes in ceramides and insulin 
signaling will provide novel insights into metabolic handling 
of HFEE in humans.
Dietary fish oil-derived n-3PUFAs may be protective 
against the responses typically observed with the devel-
opment of insulin resistance (Albert et al., 2014; Souza 
et al., 2020), but few studies have explored their role along-
side short-term high-fat overfeeding. Dietary fish oil has 
a triglyceride lowering effect (Harris,  1996, 1997), even 
with high-fat diets (Turvey et al.,  2005), and the n-3PUFA 
composition of skeletal muscle membranes positively cor-
relates with insulin sensitivity (Borkman et  al.,  1993). 
Eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) 
fish oil supplement strategies in previous studies have var-
ied from 4g/d over 8 weeks (Smith et al., 2011) to 5g/d over 
4 weeks (McGlory et al., 2014), and even 50g/d over only 
3  days (Turvey et  al.,  2005). All of these studies have ob-
served increases in muscle n-3PUFA phospholipid fractions 
and/or skeletal muscle metabolic effects. Thus, evaluating the 
influence of n-3PUFA intake on early adaptations to HFEE 
using a high-dose, short-term fish oil ingestion approach will 
p = .048). A time by group interaction was observed for PKB activity (p = .003), 
with increased activity following HFEE in HF-C (4.5 ± 13.0mU/mg) and decreased 
activity in HF-FO (−10.1 ± 20.7 mU/mg) following HFEE. Basal AMPKα2 activity 
increased in HF-FO (4.1 ± 0.6 to 5.3 ± 0.7mU/mg, p = .049), but did not change in 
HF-C (4.6 ± 0.7 to 3.8 ± 0.9mU/mg) following HFEE. We conclude that early skel-
etal muscle signaling responses to HFEE appear to be modified by dietary n-3PUFA 
content, but the potential impact on future development of metabolic disease needs 
exploring.
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inform our understanding of the influence of dietary fat com-
position, during high-fat overfeeding, on the regulation of 
glucose and fat metabolism.
The primary aim of this study was to evaluate short-term 
changes in whole-body glucose handling and insulin sen-
sitivity following HFEE with or without high-dose fish oil 
supplementation. The secondary aim was to investigate the 
muscle lipid composition and activity of intracellular signal-
ing proteins known to regulate metabolism following short-
term HFEE. Both of these aims were designed to understand 
the impact of manipulating dietary n-3PUFA content on the 
metabolic response to short-term HFEE. We hypothesized 
that: 1) HFEE for 6 d would reduce whole-body insulin sen-
sitivity/ glucose disposal, through alterations in skeletal mus-
cle lipid composition that would negatively affect the activity 
of intracellular proteins involved in insulin signaling, and; 2) 
substitution of 10% of total fats with dietary n-3PUFAs ob-
tained from fish oil would offset these negative responses.
2 |  METHODS
2.1 | Participants and ethical approval
Twenty healthy, young, moderately active men with no fam-
ily history of T2D were recruited from the University of 
Stirling and surrounding area (Table  1). Following health 
screening and dietary analysis, participants were excluded 
from the study if their fasting blood glucose concentration 
was > 6.1 mmol/L, they habitually consumed a diet high in 
n-3PUFA sources, consumed n-3PUFA supplements, exer-
cised for more than 150 min per week, or were actively try-
ing to gain or lose body mass. Ethical approval was obtained 
from the NHS East of Scotland Research Ethics Service 
(REC 2) and the study was conducted in accordance with 
the Declaration of Helsinki. Participants provided written in-
formed consent for their participation once the study purpose 
and procedures had been explained in lay terms.
2.2 | Study design
In a randomized, parallel study design, participants were as-
signed to either a high-fat control (HF-C; n = 10) or a high-
fat fish oil (HF-FO; n  =  10) group. Groups were matched 
based on age, body mass, habitual physical activity, and en-
ergy intake. Both groups were provided with a baseline diet 
replicating their habitual diet for 3d, followed by a high-fat 
energy excess (HFEE) diet for 6d. Before and after the 6d 
HFEE diet, identical testing days were conducted that in-
cluded infusion trials combined with an oral glucose toler-
ance test (OGTT, Figure 1).
Participants arrived at the laboratory between 06:00 and 
08:00 h following a ~10h overnight fast. Dietary compliance 
was confirmed verbally prior to beginning the trial, nude body 
mass was recorded, and a dual-energy x-ray absorptiometry 
(DXA) scan (LUNAR iDXA; GE Healthcare Systems, UK) 
was performed to measure body composition. With partici-
pants positioned supine on a bed, a catheter was inserted into 
a forearm vein for collection of a basal venous blood sample 
followed by a primed (13.5 µmol/kg) continuous 3h infusion 
(0.350  µmol·kg−1·min−1) of [6,6-2H2] glucose (Cambridge 
Isotope Laboratories, MA, USA) using an Alaris PK infusion 
pump (CareFusion, CA, USA). During the first hour of infu-
sion, a second catheter was inserted into the contralateral arm 
for repeated venous blood sampling. A venous blood sample 
was obtained at –30 min (30 min into infusion but 30 min 
before beginning the OGTT). One hour into the infusion 
(0 min), participants consumed a test drink containing 73 g 
glucose + 2 g [U-13C] labeled glucose in 300 ml water over 
a 5-min period to start the OGTT. Fluid intake was restricted 
to only the OGTT drink throughout the trial. During the 2-h 
period following OGTT drink ingestion, blood samples were 
drawn every 10  min until the continuous glucose infusion 
was stopped (2-h post glucose OGTT drink consumption). 
On both trial days, muscle biopsies were collected before the 
OGTT (i.e., in the basal state) to evaluate skeletal muscle 
phospholipid composition, skeletal muscle ceramide content, 
maximal activity of mitochondrial enzymes (citrate synthase 
and β-hydroxyacyl-CoA dehydrogenase), and kinase activity 
of AMPKα2 and PKB. Biopsies taken after the 2 h OGTT 
protocol (i.e., in the insulin-stimulated state) were used to as-
sess the kinase activity of PKB.
2.2.1 | Dietary assessment and composition
Food was provided to participants in daily food bags for a 9d 
period (3d baseline diet, 6d HFEE). As food was mostly con-
sumed away from the laboratory, participants were instructed 
to solely consume the food and drink items provided dur-
ing the experiment, and to consume the entirety of the food 
bag provided each day. All participants verbally confirmed 
T A B L E  1  Participant characteristics on entry into the study for 
high-fat control (HF-C, n = 10) and high-fat fish oil (HF-FO, n = 10) 
groups
HF-C HF-FO
Age (y) 21.8 ± 3.4 22.9 ± 3.7
Body mass (kg) 72.4 ± 7.7 70.1 ± 7.9
BMI (kg·m−2) 21.8 ± 2.0 21.3 ± 2.0
Physical activity (h/wk) 1.1 ± 0.4 1.2 ± 0.4
Fasting insulin (µIU/ml) 12.6 ± 5.1 11.1 ± 2.9
Fasting glucose (mM) 5.0 ± 0.3 4.9 ± 0.4
Note: Values are means ± SD. No differences were observed in any parameter 
between groups.
4 of 15 |   WARDLE Et AL.
consumption of their prescribed intake when collecting a new 
food bag.
Energy intake for the control and experimental diets was 
estimated from a 3d food (2 weekdays, 1 weekend day) and 
physical activity diary that participants completed prior to 
baseline testing. Food diaries were analyzed using com-
mercially available dietary analysis software (Microdiet, 
Downlee Systems Ltd, UK) for average daily energy intake 
and macronutrient contributions. The 3d baseline diet was 
matched to participants’ habitual energy intake and macro-
nutrient composition. The 6d high-fat control (HF-C) and 
high-fat fish oil (HF-FO) diets were consumed between the 
2 testing days, and comprised 150% of habitual energy in-
take, with 60% of energy from fat, 25% from carbohydrate, 
and 15% from protein. The HF-FO group had 10% of total 
fats in the diet (6% total energy) replaced by dietary fish 
oil, whereas HF-C received the 60% fat from a mixture 
of sources, excluding foods highly enriched with n-3PU-
FAs. Dietary fish oil was provided by means of oily fish 
consumption (salmon (1:2 ratio of EPA to DHA), mack-
erel (1:1 ratio of EPA to DHA), fish oil supplement (1:1 
ratio of EPA to DHA) added to yoghurt-based smoothies, 
and omega-3 enriched juices containing 1,000mg EPA and 
1,000mg DHA (Smartfish Nutrition, Norway). Placebo 
drinks (Smartfish Nutrition, Norway) without any omega-3 
oil were provided to participants in HF-C.
2.3 | Blood and skeletal muscle 
sampling and processing
Blood samples were drawn at baseline and every 10 min dur-
ing the OGTT and dispensed into EDTA vacutainers (Becton, 
Dickinson & Company, NJ, USA). One basal blood sample 
was retained as whole blood for lipid analysis. All other 
blood samples were centrifuged at 3,500 rpm for 15 min at 
4°C, the plasma removed, and then aliquoted into Eppendorf 
tubes for storage at −80°C pending analysis of glucose and 
insulin concentrations.
For the muscle biopsy, a 5-mm Bergström needle was in-
serted through a pre-prepared anaesthetized (2% Lidocaine) 
incision in the skin and fascia, into the muscle belly of the 
vastus lateralis and a muscle tissue sample was removed 
under manual suction. Muscle tissue was immediately 
rinsed using ice-cold saline (0.9%) and any visible fat or 
connective tissue was removed. Samples were blotted, split 
into smaller pieces and weighed before freezing as aliquots 
in liquid nitrogen prior to storage at −80°C pending analy-
sis. Both biopsies taken on the trial day (basal (0 min) and 
insulin-stimulated (120 min)) were removed from the same 
leg, but from separate incision sites. For infusion trial 2 
(post-HFEE), biopsies were obtained from the contralateral 
limb.
2.4 | Plasma glucose kinetics and 
concentrations, insulin concentrations and 
insulin sensitivity
2.4.1 | Plasma glucose and serum 
insulin analyses
Plasma glucose concentration was assessed spectrophoto-
metrically using the glucose oxidase method on an ILab 
Aries benchtop analyzer (Instrumentation Laboratories, MA, 
USA). Samples were analyzed in duplicate for each 10 min 
sample interval during the OGTT (0–120  min). Serum in-
sulin concentration was measured at the same time-points 
by ELISA method according to manufacturer's instructions 
(Demeditic (DE2935), Germany).
F I G U R E  1  (a) Study design; and 
(b) infusion trial schematic. Both groups 
(high-fat control [HF-C] and high-fat fish 
oil [HF-FO]) completed all aspects depicted, 
with the only difference between groups 
being the n-3PUFA fat content provided in 
the experimental diet. The beverage ingested 
in the infusion trial was a standard 75 g 
glucose in 300 ml water.
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2.4.2 | Plasma glucose kinetics
Plasma enrichments of [6,6-2H2] glucose from the infusion 
and [U-13C] glucose from the glucose drink were measured 
by GCMS following preparation of pentacetate derivatives 
using 2:1 acetic anhydride:pyridine (v/v). Plasma glucose 
enrichments were quantified using GCMS with chemi-
cal ionization. Ions were selectively monitored at mass 
to charge ratios of 331.1 (M + 0), 332.1 (M + 1), 333.1 
(M + 2), 334.1 (M + 3), and 337.1 (M + 6) based on the 
masses of the labeled isotopes, and potential for carbon 
recycling. Plasma glucose enrichments for each ion were 
expressed relative to enrichments at 331.1 (M + 0). A skew 
correction factor was applied to the U-13C enrichments 
(337.1; M  +  6) to account for differences in the relative 
distribution of the mass spectra between the tracer (U-13C) 
and tracee (unlabeled glucose). The GC System (7890A; 
Agilent Technologies, CA, USA) was interfaced with a 
5975C MS inert XL EI/CI MSD with a triple-axis detec-
tor. Methane gas was used for positive ionization, with 
helium as the carrier gas. Chemstation software (Agilent 
Technologies, CA, USA) was used for data analysis.
2.4.3 | Insulin sensitivity
Insulin sensitivity (or resistance) was estimated from 
the Matsuda Insulin Sensitivity Index (ISI; (Matsuda & 
DeFronzo,  1999)), HOMA-IR (Matthews et  al.,  1985), 
HOMA-β (Matthews et al., 1985), Hepatic Insulin Resistance 
(IR) index (Abdul-Ghani et al.  2007), and Hepatic Insulin 
Sensitivity (IS) index (Faerch et al., 2010) using basal 
and insulin-stimulated plasma glucose and serum insulin 
concentrations.
2.5 | Blood and skeletal muscle lipid analysis
Fatty acid methyl esters (FAME) were extracted from whole 
blood lipids using the Rapid Omega Test, as previously de-
scribed (Bell et al., 2011). Total lipids were extracted from skele-
tal muscle homogenates (Folch, Lees, & Sloane Stanley, 1957), 
with non-lipid impurities removed by washing with 0.88% 
(w/v) KCl. Phospholipids were isolated using thin layer chro-
matography as described previously (Bell et al., 2011).
FAME from blood and skeletal muscle tissue were 
separated by GLC using a ThermoFisher Trace GC 2000 
(ThermoFisher, Hemel Hempstead, UK) equipped with a fused 
silica capillary column (ZBWax, 60 m x 0.32 x 0.25 mm i.d.; 
Phenomenex, Macclesfield, UK). Hydrogen was used as car-
rier gas with on-column injection. Individual methyl esters 
were identified from previously published data (Ackman 
et al., 1980) and the Chromcard for Windows (version 2.00) 
computer software (Thermoquest Italia S.p.A., Milan, Italy) 
was used for data collection and processing.
2.6 | Skeletal muscle ceramide analyses
Total lipids were extracted from skeletal muscle homogenates 
(Folch et al., 1957) with non-lipid impurities removed by wash-
ing with 0.88% (w/v) KCl. C17:0 ceramide (Avanti Polar Lipids 
Inc., Alabaster, AL, USA) was added as an internal standard. 
Ceramides were isolated using solid-phase extraction chro-
matography (100 mg, 3 mL silica columns, Biotage, Uppsala, 
Sweden) and eluted in 5-mL chloroform/ ethyl acetate (1:1) 
prior to quantification by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) as described previously (Mcilroy 
et al., 2016). All analyses were performed on a Thermo TSQ 
Quantum Ultra triple quadrupole mass spectrometer interfaced 
to a Thermo Accela 1250 UHPLC system in positive ion mode. 
Individual ceramide species were separated on a Kinetex C8 
LC column (100 x 2.1mm x 2.6µm, Phenomenex, Macclesfield, 
UK) using an acetonitrile/ water gradient and detected through 
multiple reaction monitoring (MRM). The data were processed 
using Thermo Xcalibur 2.1 Quan Browser software.
2.7 | Skeletal muscle mitochondrial 
enzyme assays
Skeletal muscle samples (5–12  mg) were homogenized in 
100 µl of homogenizing solution per 1-mg wet weight mus-
cle (1.36  g of 0.1  M KH2PO4  +  50  mg of BSA in 80-mL 
ddH2O; pH adjustment to 7.3 with KOH before adding ad-
ditional ddH2O to achieve a final volume of 100 ml) using 
an automated homogenizer with 1.4-mm (green) ceramide 
beads (MagNaLyser, Roche, Germany). Samples were ho-
mogenized on ice twice at 7,000 rpm for 10 s, separated by 
1 min on ice. Following homogenization, all samples were 
centrifuged at 12266 g at 4°C for 20 s. Homogenates were 
snap-frozen in liquid nitrogen before performing two freeze/ 
thaw cycles. Following the final thaw, homogenates (300 
µl) were transferred into individual glass vials (cuvettes) 
for analysis and positioned in the sample rotor according to 
the work list schedule on an ILab Aries benchtop analyzer 
(Instrumentation Laboratories, MA, US). Twenty-five micro-
liters of muscle homogenate was used for each reaction. The 
work list schedule and homogenate sample were the same for 
both the citrate synthase and β-HAD reactions.
2.8 | Citrate synthase (CS)
Two-hundred and twenty-five microliters of reagent 1 
(TRIS buffer (pH 8.3; 7.5 ml), DTNB (1.25 ml), acetyl-CoA 
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(2 ml), and Triton X-100 (10%; 500 µl)) and the muscle ho-
mogenate (10 µl) were combined initially, before adding 15 
µl of 10-mM oxaloacetate (reagent 2) to start the reaction. 
Readings were taken at 450 nm at selected intervals (0, 39, 
52, 65, 78, 91, 104, 130, 156, 182 195, 234, 260 s) over a 
5-min period.
2.9 | β-Hydroxyacyl-CoA Dehydrogenase 
(β-HAD)
Two-hundred and fifteen microliters of reagent 1 (TRIS-HCl 
buffer (pH 7.0; 2.5 ml), EDTA (0.5 ml), NADH (2.5 ml) and 
ddH2O (19.5 ml)) and 5 µl of reagent 2 (Triton x-100 (10%)) 
were combined with the muscle homogenate (25 µl) for an in-
itial 5-min incubation period before taking a slope measure-
ment at 340 nm for 2 min to record steady state. Next, 5 µl of 
5-mM acetoacetyl-CoA (reagent 3) was added to start the re-
action and the decrease in NADH was measured. Absorbance 
readings at 450 nm were obtained at regular intervals over a 
2.5-min period for determination of β-HAD.
2.10 | Skeletal muscle [γ-32P] ATP kinase 
activity assays
PKB and AMPK activities were measured using methods 
previously described (McGlory et al., 2014).
2.11 | Statistical analyses
All data were tested for normality using the Ryan Joiner test 
with Minitab software (version 16; Minitab, State College, 
PA). In the case of non-normally distributed data, Box-Cox 
transformations were applied before testing for normality a 
second time. A two-way repeated measures ANOVA (IBM 
SPSS Statistics v19, NY, USA) was used to assess differ-
ences between groups [HF-C versus HF-FO] and over time 
[pre-HFEE versus post-HFEE]. In the case of a significant 
interaction effect, paired samples t-tests were conducted to 
assess differences over time within each group alone. A two-
tailed Pearson correlation coefficient was used to assess the 
relationship between pre-HFEE CS activity or β-HAD activ-
ity and the pre- to post-HFEE change in whole-body indices 
of insulin sensitivity, skeletal muscle ceramide content, and 
skeletal muscle PKB and AMPKα2 activity. Statistical sig-
nificance was assumed at the level of p < .05. All values are 
presented as mean ± standard deviation (SD), unless stated 
otherwise.
3 |  RESULTS
3.1 | Participant characteristics, dietary 
intake and body composition
Participant characteristics for the HF-C and HF-FO groups 
on enrolment into the study are presented in Table 1. Dietary 
energy intake was increased by 150% (HF-C: 10,937 ± 2,381 
to 16,397  ±  3,573  kJ/d; HF-FO: 10,222  ±  1,741 to 
15,305 ± 2,690 kJ/d) with 60% of energy provided from fat. 
As intended, dietary n-3PUFA intake was greater (p = .0001) 
in HF-FO (25  ±  2  g) versus HF-C (2  ±  0  g) (Table  2). 
Measurements of total body mass (HF-FO: p = .003; HF-C: 
p  =  .045) and total fat mass (HF-FO: p  =  .016; HF-C: 
p  =  .013) increased in response to HFEE, irrespective of 
group (Table  3), with significant gains in trunk fat mass 
(p = .033) and android fat (p = .001) observed in HF-C, and 
significant gains in limb fat mass in HF-FO (p = .015).
Baseline diets Experimental diets
HF-C HF-FO HF-C HF-FO
Energy (kJ/d) 10,937 ± 2,381 10,222 ± 1,741 16,397 ± 3,573† 15,305 ± 2,690† 
Fat 104 ± 29 87 ± 15 261 ± 57† 245 ± 43† 
SFA 42 ± 11 33 ± 10 106 ± 22† 100 ± 16† 
MUFA 31 ± 11 24 ± 6 74 ± 14† 69 ± 14† 
PUFA 10 ± 5 11 ± 6 31 ± 8† 38 ± 10† 
n−3 PUFA 0 ± 0 0 ± 0 2 ± 0† 25 ± 6† ,*
Carbohydrate 323 ± 71 325 ± 105 263 ± 57† 244 ± 42† 
Sugars 119 ± 39 133 ± 61 121 ± 22 77 ± 6† ,*
Protein 116 ± 41 108 ± 22 146 ± 33† 137 ± 24† 
Note: Values are means ± SD and reported as g/d unless otherwise indicated. Values displayed as 0 
were < 0.5g/d.
† Significantly different from baseline diet within each group.  
* Significantly different from HF-C for equivalent condition, p < .05.  
T A B L E  2  Daily diet composition over 
3 d of baseline diets and 6 d of experimental 
diets for the high-fat control (HF-C, n = 10) 
and high-fat fish oil (HF-FO, n = 10) 
groups.
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3.2 | Insulin sensitivity and plasma 
glucose kinetics
Insulin sensitivity, assessed using Matsuda ISI, did not 
change following HFEE (HF-C: 3.96 ± 1.85 to 3.59 ± 1.50, 
p = .480; HF-FO: 3.81 ± 1.16 to 3.94 ± 1.09, p = .720) and 
was not different between groups. No difference was ob-
served pre- to post-HFEE when insulin sensitivity was as-
sessed using HOMA-IR, HOMA-β, Hepatic-IR index, and 
Hepatic-IS index (data not shown). Insulin and glucose re-
sponses to the OGTT conducted pre- and post-HFEE did 
not demonstrate any clear differences in glucose handling, 
nor between groups (Figure 2). No significant associations 
were observed between pre-HFEE CS or β-HAD activ-
ity and the pre- to post-HFEE change in Matsuda ISI or 
HOMA-IR.
Plasma glucose kinetics data, evaluated using dual-glu-
cose isotopic tracer analysis, are presented in Table 4. The 
AUC and peak plasma glucose concentrations for total Ra, 
exogenous Ra, endogenous Ra, and total Rd did not change 
following HFEE, irrespective of group. However, the time 
point at which exogenous glucose Ra peaked following oral 
glucose consumption was delayed following HFEE in the 
HF-FO group only (p = .037).
3.3 | Lipid profiles
3.3.1 | Blood
A full blood fatty acid profile is presented in Table S1. Total 
n-3PUFAs (when expressed as a percentage of total FAs) 
were increased in HF-FO (p < .0001) following HFEE, with 
no change in HF-C (Figure 3a). An increased content of EPA 
(0.57 ± 0.40 to 3.95 ± 1.20%, p < .0001), DPA (1.40 ± 0.20 
to 1.56  ±  0.14%, p  =  .0001), and DHA (2.51  ±  0.44 to 
4.21  ±  0.58%, p  <  .0001) primarily contributed to the in-
crease in total blood n-3PUFAs observed in HF-FO. The 
AA:EPA ratio, representative of the n-6:n-3 PUFA ratio, was 
decreased in HF-FO over time (20.14 ± 4.98 to 3.01 ± 1.06, 
p < .0001), with no significant change in HF-C (16.66 ± 3.71 
to 15.23 ± 2.83, p = .0872).
3.3.2 | Skeletal muscle
A full skeletal muscle phospholipid profile is presented in 
Table S2. Total SFA, total MUFA, and total n-6 PUFAs 
did not change following HFEE and were not different 
between groups. An increase in n-3PUFA content in the 
phospholipid membrane of the HF-FO group was observed 
following HFEE (Figure  3b, p  =  .040), with no change in 
HF-C (p =  .740). Specifically, EPA content was increased 
(p = .015), but AA was unchanged (p = .240) in the HF-FO 
group following HFEE, with no changes in either within the 
HF-C group. There was also no change in DHA content in 
HF-FO (p =  .260) or HF-C (p =  .740). The AA:EPA ratio 
decreased in the HF-FO group (p = .037) over time with no 
change in HF-C (p = .760).
3.4 | Mitochondrial enzyme activities
Complete data for citrate synthase and β-HAD activity were 
obtained from only n = 17 participants (n = 9 HF-FO and 
n  =  8 HF-C) due to availability of muscle tissue. In the 
basal state (0 min), enzyme activities were not changed by 
HFEE in either group (Table  5). Mean pre-HFEE activity 
of both mitochondrial enzymes were consistent with maxi-
mal activity values for moderately active individuals (Perry 
HF-C HF-FO
Pre-HFEE Post-HFEE Pre-HFEE Post-HFEE
Total body mass 
(kg)
71.74 ± 11.38 72.25 ± 11.54† 69.65 ± 7.35 70.67 ± 7.24† 
Total fat mass 
(kg)
13.87 ± 3.52 14.16 ± 3.43† 14.40 ± 5.23 14.85 ± 5.08† 
Limb fat mass 
(kg)
6.94 ± 1.55 7.01 ± 1.56 7.40 ± 2.40 7.66 ± 2.42† 
Trunk fat mass 
(kg)
6.07 ± 2.28 6.27 ± 2.21† 6.12 ± 2.85 6.29 ± 2.67
Android fat (%) 16.89 ± 7.54 17.88 ± 7.25† 17.63 ± 8.96 18.22 ± 8.62
Total lean mass 
(kg)
55.30 ± 9.58 55.55 ± 9.71 52.89 ± 6.25 53.44 ± 5.86
Note: Values are mean ± SD. No differences were observed between groups pre- or post-HFEE.
†significantly different from pre-HFEE within group, p < .05. 
T A B L E  3  Body composition for 
high-fat control (HF-C, n = 10) and high-fat 
fish oil (HF-FO, n = 10) groups at baseline 
before (Pre-HFEE), and following (Post-
HFEE) 6 days of high-fat energy excess.
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et al., 2007; Talanian et al., 2007); i.e. >20 µmol·g-1·min-1 for 
CS, and > 10 µmol·g-1·min-1 for β–HAD).
3.5 | Skeletal muscle ceramides
Total basal skeletal muscle ceramide content increased by 
69 ± 32% following HFEE, irrespective of group (Figure 4a). 
Statistical analysis of individual species revealed significant 
increases in the fold change for species C22:0, C23:0, and 
C24:1 (p = .033, .021, and .019, respectively) from pre- to 
post-HFEE (Figure 4b), irrespective of group. An inverse re-
lationship existed between basal CS activity and the increase 
in muscle ceramide content in response to 6 d of HFEE 
(r = −0.51, p = .037, Figure 4c).
3.6 | PKB and AMPK α2 activity
PKB activity was greater in the insulin-stimulated state (2 hr) 
than basal state (0 hr), irrespective of group, but did not reach 
statistical significance (p = .051; Figure 5a). However, a sig-
nificant time-by-group interaction (p = .025) was observed, 
with PKB activity decreasing in HF-FO but increasing in 
HF-C from pre- to post-HFEE (mean difference (95% CI) 
+4.5 (−2.0 to +10.9) mU.mg-1 for HF-C and −10.1 (−20.4 
to + 0.2) mU.mg-1 for HF-FO, Figure 5a). No difference in 
the change in PKB activity following insulin stimulation was 
observed between groups (Figure 5b). No association was ob-
served between pre-HFEE CS activity and the change in PKB 
activity pre- to post-HFEE in either group (data not shown).
Basal (0 min) skeletal muscle AMPKα2 activity was un-
changed following HFEE in HF-C, but increased in HF-FO 
(mean difference (95% CI) −0.8 (−2.3 to  +  0.8) mU.mg-
1 for HF-C and + 1.2 (+0.9 to +2.3) mU.mg-1 for HF-FO, 
Figure 5c; interaction effect: p = .038). No association was 
observed between pre-HFEE CS activity and the change in 
AMPKα2 activity pre- to post-HFEE (r = 0.112, p = .690).
4 |  DISCUSSION
We report physiologically important early signs of metabolic 
disturbance in skeletal muscle of moderately active individu-
als fed a HFEE diet for 6 d. Skeletal muscle ceramide con-
tent was increased following HFEE, irrespective of whether 
10% of dietary fat was derived from n-3PUFAs. The increase 
in ceramide content was inversely associated with skeletal 
F I G U R E  2  (a) Serum insulin and (b) plasma glucose concentration during the oral glucose tolerance test conducted before (Pre-HFEE) and 
after (Post-HFEE) high-fat energy excess in the high-fat control (HF-C) group. (c) Serum insulin and (d) plasma glucose concentration during the 
oral glucose tolerance test conducted before (Pre-HFEE) and after (Post-HFEE) high-fat energy excess in the high-fat fish oil (HF-FO) group. No 
significant trial (pre- to post-HFEE), or interaction (trial by group) effects were noted.
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muscle oxidative capacity, as determined by the maximal 
activity of citrate synthase. However, despite modest in-
creases in ceramide content, no changes were noted in indi-
ces of whole-body insulin sensitivity, or in glucose disposal/ 
kinetics. Differential responses in basal intramuscular PKB 
and AMPKα2 activity between HF-C and HF-FO suggest 
that the lipid composition of HFEE diet impacts upon early 
metabolic disturbances in cellular signaling pathways. Our 
findings provide insight into early localized (skeletal muscle) 
cellular changes in response to HFEE and provide the basis 
for more research investigating the potential for n-3PUFAs to 
positively modulate intracellular signaling responses during 
whole-body exposure to caloric excess.
4.1 | Dietary intake and skeletal muscle 
lipid composition
Skeletal muscle ceramide content is closely linked with 
insulin resistance in skeletal muscle (Blachnio-Zabielska 
et al., 2010) and liver (Zabielski et al., 2019). In the present 
study, the ceramide content of skeletal muscle increased 
over the 6 d of HFEE in both groups. Ceramide synthesis 
is complex with de novo synthesis resulting from a range of 
ceramide synthases that catalyze the formation of ceramide 
species from long chain fatty acids (Hannun & Obeid, 2008). 
An abundance of dietary lipids, in excess of capacity for 
oxidation, leads to a surplus of the ceramide precursor fatty 
acyl-CoAs and subsequent upregulation of ceramide syn-
thesis. Indeed, we observed an inverse association between 
the oxidative capacity of skeletal muscle and the increase 
in ceramide content in skeletal muscle. Our observations 
highlight that, in men who are moderately active, the muscle 
capacity for lipid oxidation is an important factor in the meta-
bolic response to HFEE. Our data suggest that higher basal 
mitochondrial oxidative capacity may provide some protec-
tion against increases in ceramide content when exposed to 
HFEE diets. This observation is consistent with the conclu-
sions of prior work demonstrating regular habitual physical 
activity can prevent pathophysiological outcomes associated 
with diet-induced increases in body mass (Krogh-Madsen 
et al., 2014).
Our data support findings from previous literature (Dzamko 
& Steinberg, 2009; Turner et al., 2007) by demonstrating that 
short-term (6 d) hyper-caloric diets do not drive changes in 
mitochondrial biogenesis in humans. Interestingly, although 
skeletal muscle ceramide content increased, there were no dif-
ferences in ceramide accumulation between HF-C and HF-FO 
groups. This lack of difference between groups likely reflects 
a similar imbalance between ceramide synthesis and metabo-
lism in both of our HFEE situations. In the present study, the 
main ceramide species that were elevated in response to HFEE 
were long chain ceramides (C22:0, C23:0, and C24:1). Long 
chain ceramide synthesis arises from the activity of ceramide 
synthase 2 which shows remarkable specificity to longer chain 
(C20-C26) acyl-CoAs (Laviad et al., 2008). Unfortunately, we 
were unable to examine the specific cellular locations of these 
ceramide species to identify potential differences between 
treatment groups. However, it is noteworthy that an increase 
in ceramide synthesis has been proposed to alter the activity 
HF-C HF-FO
Pre-HFEE Post-HFEE Pre-HFEE Post-HFEE
Glucose AUC(0−120 min) (mg·min
−1·kg−1:120 min)
Total Ra 209.9 ± 67.9 195.6 ± 63.1 208.7 ± 79.9 213.3 ± 89.3
Exogenous Ra 318.2 ± 66.8 310.4 ± 46.4 349.9 ± 71.4 352.0 ± 88.1
Endogenous Ra 113.0 ± 26.0 118.4 ± 34.2 143.1 ± 39.8 139.0 ± 21.2
Total Rd 255.1 ± 89.0 278.2 ± 77.7 273.3 ± 90.7 283.2 ± 101.4
Peak glucose appearance/disappearance (mg·min−1·kg−1)
Total Ra 6.47 ± 1.03 6.51 ± 0.82 7.11 ± 1.20 6.98 ± 1.36
Exogenous Ra 4.56 ± 0.94 4.81 ± 0.87 5.17 ± 1.12 5.34 ± 1.14
Endogenous Ra 3.55 ± 0.40 3.47 ± 0.34 3.77 ± 0.46 3.67 ± 0.29
Total Rd 6.69 ± 1.21 6.63 ± 0.89 7.34 ± 1.52 7.18 ± 1.58
Time point corresponding to peak plasma glucose appearance/disappearance (minutes)
Total Ra 83 ± 29 95 ± 33 84 ± 30 100 ± 20
Exogenous Ra 105 ± 21 116 ± 13 95 ± 26 115 ± 13*
Endogenous Ra 15 ± 5 13 ± 5 13 ± 5 11 ± 3
Total Rd 77 ± 18 87 ± 25 85 ± 24 97 ± 19
Note: Values are means ± SD.
*Significantly different from Pre-HFEE: main effect of time (p = .037) by ANOVA. 
T A B L E  4  Plasma glucose kinetics data 
from baseline (Pre-HFEE) and following 
6 days of high-fat energy excess (Post-
HFEE) in the high-fat control (HF-C, 
n = 10) and high-fat fish oil (HF-FO, 
n = 10) groups.
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of many different kinases (Schubert et al., 2000). Therefore, 
increases in ceramide synthesis would be expected to impact 
upon cellular signaling pathways in the context of HFEE, as 
modeled in the present study.
4.2 | Dietary intake, glucose disposal and 
cellular signaling
Despite the increases in skeletal muscle ceramide content with 
HFEE, we failed to detect a difference in whole-body glucose 
disposal or glucose kinetics during the OGTTs. While other 
studies have demonstrated an effect of short-term high-fat 
diets on glucose handling (Bachmann et al., 2001; Hulston 
et  al.,  2015; Parry et  al.,  2017, 2019), this outcome is not 
consistent across all studies (Adochio et  al.,  2009; Bakker 
et al., 2014; Brøns et al., 2009; Cornier et al., 2006). Studies 
reporting perturbed glucose handling following HFEE were 
of similar duration (6–7 d), and similar energy surplus (~50%) 
and fat content (~60%–65%) to the present study. However, 
These studies recruited a range of physically active partici-
pants (Hulston et  al.,  2015; Parry et  al.,  2017, 2019), used 
mixed-sex participant groups (Hulston et  al.,  2015; Parry 
et al., 2017, 2019), and, in some instances, calculated energy 
provision from estimated energy requirements rather than 
from food / activity diary records (Parry et al., 2017, 2019). 
Thus, several methodological aspects may contribute to the 
differences in findings between studies (notably mixed-sex 
samples), which should be considered in the design of future 
studies that utilize short-term HFEE as a model to investigate 
early responses to overfeeding.
The absence of a difference in glucose handling over 6-d 
HFEE may reflect the specific ceramide species affected by 
our HFEE diets. Typically, C16 or C18 ceramides are asso-
ciated most strongly with changes in tissue insulin sensitiv-
ity (Straczkowski et  al.,  2004), and PKB activity would be 
expected to be downregulated by increases in C16 or C18 
ceramides. In the present study, PKB activity was differ-
entially regulated between treatment groups with an inter-
action effect for PKB activity. In the absence of significant 
increases in the C16 and C18 ceramide species, we would 
not expect to observe a downregulation of PKB activity by 
HFEE. However, an apparent downregulation of PKB kinase 
activity was evident in the HF-FO group despite no differ-
ence in C16 and C18 ceramide content. This downregulation 
of PKB kinase in the HF-FO group could reflect a positive 
change in the responsiveness/ efficiency of the intracellular 
signaling cascade. This hypothesis appears consistent with 
the observation of similar glucose handling and glucose ki-
netics observed during the OGTT, despite reduced basal and 
post-OGTT PKB activity in the HF-FO group. Alternatively, 
it could be interpreted that greater PKB activity was required 
in the HF-C group to achieve the same level of glucose con-
trol. Either way, the differential response in PKB activity 
F I G U R E  3  (a) Combined EPA, DPA, and DHA composition of 
whole blood pre- and post-HFEE for both high-fat control (HF-C) and 
high-fat fish oil (HF-FO) groups (n = 10 per group); and (b) combined 
EPA, DPA and DHA composition of skeletal muscle phospholipid 
membrane fraction pre- and post-HFEE for both HF-C and HF-FO 
groups (n = 9 per group). Data are expressed as median, 25th-75th 
centile (box) and range (whiskers) and represent % of total fatty acids 
(FAs). ** significantly different p = .000002, and * significantly 




Pre-HFEE Post-HFEE Pre-HFEE Post-HFEE
Citrate synthase
(µmol·g−1·min−1)
29.65 ± 9.41 27.51 ± 9.27 30.69 ± 5.70 27.78 ± 8.87
β-HAD
(µmol·g−1·min−1)
13.57 ± 3.94 14.44 ± 2.82 14.67 ± 1.87 14.07 ± 2.75
Note: Values are means ± SD. No significant differences were detected between groups or over time.
T A B L E  5  Basal skeletal muscle 
mitochondrial enzyme maximal activity 
before (Pre-HFEE) and after (Post-HFEE) 
high-fat energy excess for high-fat control 
(HF-C, n = 8) and high-fat fish oil (HF-FO, 
n = 9) groups.
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between HF-C and HF-FO from pre- to post-HFEE most 
likely reflects differences in skeletal muscle phospholipid 
membrane incorporation of n-3PUFAs, and/ or subsequent 
changes in skeletal muscle n-6:n-3 ratio. Supporting this no-
tion, our previous work (McGlory et al., 2016) revealed an 
alteration in the efficiency of the signaling cascade following 
8 wk of n-3PUFA supplementation, and demonstrated a re-
duced skeletal muscle intracellular signaling response (i.e., 
mTORC1 and p70S6k) to exogenous amino acid availability 
without a concomitant decrease in the rate of skeletal muscle 
protein synthesis. Furthermore, an attenuation of PDK activ-
ity was noted by Turvey et  al.,  (2005) without any change 
in PDHa activity following n-3PUFA ingestion as part of a 
HFEE diet. Therefore, n-3PUFA ingestion seems to dampen, 
or introduce efficiency into, signaling cascades without com-
promising functional outcomes.
AMPKα2 activity also was differentially regulated be-
tween our two diet groups, with an increased basal AMPK 
activity noted in the HF-FO group only. An increase in 
basal PKB activity can inhibit AMPK activity through 
the phosphorylation of serine 487 on the α1 subunit 
(Hardie, 2014). However, PKB does not phosphorylate the 
α2 subunit (Hawley et  al.,  2014), so a reduction in PKB 
activity would typically not be associated with an increase 
in AMPKα2 activity. In the present study, the differential 
response with increased basal AMPKα2 activity in the 
F I G U R E  4  (a) Total skeletal muscle 
ceramide content pre- and post- 6 days of 
high-fat energy excess (HFEE) in high-fat 
control (HF-C) and high-fat fish oil (HF-
FO) conditions; (b) individual ceramide 
species, presented for HF-C and HF-FO 
groups, expressed as the fold-change from 
pre- to post-HFEE; and (c) association 
between muscle maximal citrate synthase 
activity measured before 6 days of high-fat 
energy excess (HFEE) and the pre- to post-
HFEE absolute change in skeletal muscle 
total ceramide content (HF-C and HF-FO 
groups combined). Data are expressed as 
median, 25th-75th centile (box) and range 
(whiskers). n = 9 per group. * significantly 
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HF-FO group may reflect an alteration in protein kinase C 
(PKC) signaling via diacylglycerol (DAG) accumulation. 
Unfortunately, we cannot confirm this hypothesis from the 
data available. An elevation in AMPK activity would typi-
cally be associated with cellular energy stress and promote 
an increased fatty acid uptake and oxidation, and reduction 
in fatty acid synthesis (Hardie,  2014). This energy stress 
responsiveness of AMPK highlights the central role that 
AMPK plays in lipid metabolism. The increased basal ac-
tivity of AMPK in our HFEE situation was only evident 
in the HF-FO group, suggesting that increasing n-3PUFA 
consumption may offset some of the negative metabolic 
effects of HFEE diets. Notably, an increase in AMPK ac-
tivity during energy surplus could be considered a positive 
outcome. In this regard, an increased activity of AMPK 
would reduce inflammatory responses through actions on 
nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-kB; (Salminen et al., 2011)), and AMPK activa-
tors such as metformin are beneficial for improving glucose 
control (Rena et al.,  2017). However, further analysis of 
downstream targets, such as ACC2 phosphorylation status, 
would be required to confirm whether a biological action 
resulted from the differential regulation of AMPKα2 ac-
tivity. Thus, increased activity of AMPK in response to 
HF-FO diets requires further exploration, especially since 
energy excess would typically be associated with a down-
regulation of AMPK (Coughlan et al., 2013).
Finally, previous work by McGlory et al., (2014); McGlory 
et al. (2016) and Smith et al. (2011) have reported changes in 
skeletal muscle lipid membrane composition over 4–8  weeks 
with EPA rich fish oil supplementation. Smith et al. (2011) re-
ported an increase in total n-3PUFA content of the muscle lipid 
membrane fraction: increasing from 5.04% to 9.03% of total 
lipids after 8 weeks of ingesting 1.86 g EPA and 1.50 g DHA 
per day. McGlory et al. (2016) reported an increase in this same 
lipid membrane fraction from 5.53% to 11.16% after 8 weeks 
of supplementation with 3.50 g EPA and 0.90 g DHA per day. 
The present data indicate that modest changes in skeletal mus-
cle lipid membrane composition (5.73 to 7.79%) can occur in 
only 6 d when 25 g of fish oil-derived EPA/ DHA are included 
in a HFEE diet. Failure to perturb insulin sensitivity following 
short-term energy-excess in HF-C meant that we were unable 
to cleanly evaluate the potential positive effects of dietary fish 
oil in the present study. However, membrane lipid composition 
changes are likely to influence the muscle responsiveness to nu-
tritional and/ or contractile stimuli, and therefore are important 
in determining the cellular and metabolic outcomes induced by 
HFEE (Casares et al., 2019). It is worth noting that in the pres-
ent study, EPA was elevated in the muscle phospholipid fraction 
in the HF-FO group, and although AA was unchanged, these 
changes in lipid composition appear to drive metabolic benefits 
in skeletal muscle cells (Jeromson et al., 2018).
4.3 | Study limitations
It is important to acknowledge that there are several limita-
tions to our study that preclude us from making firm conclu-
sions. Firstly, we chose a short-term high HFEE diet to mimic 
short periods of overfeeding. Moreover, we replicated other 
F I G U R E  5  (a) PKB activity in the basal (0 hr) and insulin 
stimulated states (2 hr) pre- and post- 6 days of high-fat energy excess 
(HFEE) for both high-fat control (HF-C) and high-fat fish oil (HF-FO) 
groups; (b) Insulin-stimulated change in PKB activity for HF-C and 
HF-FO, pre- and post-HFEE; and (c) Basal skeletal muscle AMPKα2 
activity pre- and post-HFEE for both HF-C and HF-FO groups. Data 
are expressed as median, 25th-75th centile (box) and range (whiskers). 
n = 9 per group. # group by time interaction (pre- to post-HFEE) for 
PKB and AMPKα2 activity, p = .025 and p = .038, respectively. * 
AMPKα2 activity significantly higher at post-HFEE compared to pre-
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short-term overfeeding studies to assess the potential influence 
of lipid composition during HFEE on our primary outcomes 
(i.e., glucose handling), and to simulate typical dietary behav-
iors during seasonal holiday periods, for example, Christmas. 
In our study cohort, this methodological approach did not in-
duce large metabolic alterations in glucose handling possibly 
because of methodological differences between our study and 
other studies, such as: activity status of participants; single 
sex group design; or, methods for assessing and prescribing 
HFEE diets. Secondly, we opted to substitute 10% of all fats 
with fish oil acutely, rather than use a lower priming dose of 
fish oil over several weeks before the high-fat overfeeding pe-
riod. Although no side effects of this high fish oil dose were 
reported, we acknowledge that this n-3PUFA dosing strategy 
is not sustainable, or clinically applicable, as longer term use 
at this dose would not be recommended. Thirdly, we did not 
assess PKB activity under peak insulin stimulation but rather 
following the peak, with insulin being around 4–5 fold higher 
than basal concentrations at time of biopsy. Finally, due to the 
fairly small sample size in each group, and the repeated meas-
ures independent group design, there is a chance that some 
observations may reflect false-positive outcomes that require 
replication before firm conclusions can be made.
4.4 | Conclusions
In conclusion, the present data confirm previous observa-
tions that subcellular events resulting from HFEE precede 
the clear development of whole-body insulin resistance. 
Six days of HFEE led to increased skeletal muscle cera-
mide content, particularly the longer chain ceramide spe-
cies. Basal mitochondrial enzyme activities remained 
unchanged by HFEE in both HF-FO and HF-C groups, but 
skeletal muscle oxidative capacity was inversely associ-
ated with the fold change in skeletal muscle ceramide con-
tent, suggesting that physical activity status influences the 
response. The differentially altered basal AMPKα2 activity 
and PKB activity following HFEE in HF-FO, compared to 
HF-C, suggests early cellular/ metabolic advantages of n-
3PUFAs that could prove important during longer term pe-
riods of HFEE. It is interesting to speculate that the group 
divergence in these findings is a result of differences in the 
phospholipid membrane composition following n-3PUFA 
ingestion. Alterations in the docking efficiency of trans-
porter proteins in the plasma membrane, altered nutrient 
kinetics, and/ or signaling resulting from membrane com-
position changes all may contribute to the observed differ-
ences in kinase activity between groups. Further work is 
required to elucidate the mechanisms of lipid composition 
in the high-fat overfed state, as well as the time course, and 
cellular locations, of changes in ceramide species during 
prolonged HFEE diets.
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